Spero therapeutics to present at upcoming investor conference

Cambridge, mass., sept. 07, 2022 (globe newswire) -- spero therapeutics, inc. (nasdaq: spro), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving rare diseases and multi-drug resistant (mdr) bacterial infections, today announced that ankit mahadevia, m.d., president and chief executive officer of spero therapeutics, will present and be available for one-on-one meetings at the 24th annual h.c. wainwright global investment conference, which is taking place september 12-14, 2022. details for the presentation are as follows:
SPRO Ratings Summary
SPRO Quant Ranking